TW202102539A - 結合蛋白、其製備方法、其組合物、其用途、編碼其之核酸分子及包含核酸分子之宿主細胞 - Google Patents

結合蛋白、其製備方法、其組合物、其用途、編碼其之核酸分子及包含核酸分子之宿主細胞 Download PDF

Info

Publication number
TW202102539A
TW202102539A TW109110936A TW109110936A TW202102539A TW 202102539 A TW202102539 A TW 202102539A TW 109110936 A TW109110936 A TW 109110936A TW 109110936 A TW109110936 A TW 109110936A TW 202102539 A TW202102539 A TW 202102539A
Authority
TW
Taiwan
Prior art keywords
domain
seq
binding
protein
cancer
Prior art date
Application number
TW109110936A
Other languages
English (en)
Chinese (zh)
Inventor
進 王
戈弗雷喬納 雷尼
Original Assignee
美商伊梅塔斯科學療法公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商伊梅塔斯科學療法公司 filed Critical 美商伊梅塔斯科學療法公司
Publication of TW202102539A publication Critical patent/TW202102539A/zh

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/245—IL-1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
TW109110936A 2019-04-01 2020-03-31 結合蛋白、其製備方法、其組合物、其用途、編碼其之核酸分子及包含核酸分子之宿主細胞 TW202102539A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962827381P 2019-04-01 2019-04-01
US62/827,381 2019-04-01

Publications (1)

Publication Number Publication Date
TW202102539A true TW202102539A (zh) 2021-01-16

Family

ID=72607367

Family Applications (1)

Application Number Title Priority Date Filing Date
TW109110936A TW202102539A (zh) 2019-04-01 2020-03-31 結合蛋白、其製備方法、其組合物、其用途、編碼其之核酸分子及包含核酸分子之宿主細胞

Country Status (9)

Country Link
US (1) US11718673B2 (https=)
EP (1) EP3947449A4 (https=)
JP (1) JP2022525238A (https=)
KR (1) KR20220004067A (https=)
CN (1) CN114127107B (https=)
AU (1) AU2020252191A1 (https=)
CA (1) CA3135838A1 (https=)
TW (1) TW202102539A (https=)
WO (1) WO2020205875A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL298136A (en) 2020-05-13 2023-01-01 Bonum Therapeutics Inc Preparations of protein complexes and methods of using them
WO2022105817A1 (en) * 2020-11-18 2022-05-27 Suzhou Transcenta Therapeutics Co., Ltd. Bi-functional molecules
CN121511262A (zh) * 2023-06-28 2026-02-10 北京哲源科技有限责任公司 靶向pd-l1和il-1的双特异性抗体及其用途
WO2025119346A1 (en) * 2023-12-07 2025-06-12 LaNova Medicines Limited Anp-dependent antibodies

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2714738B1 (en) * 2011-05-24 2018-10-10 Zyngenia, Inc. Multivalent and monovalent multispecific complexes and their uses
JP2016514676A (ja) 2013-03-15 2016-05-23 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ 四価二重特異性抗体
WO2015035365A1 (en) * 2013-09-09 2015-03-12 The Nohns Hopkins University Targeting the m2-tumor associated macrophage for cancer therapy
US10227411B2 (en) * 2015-03-05 2019-03-12 Xencor, Inc. Modulation of T cells with bispecific antibodies and FC fusions
BR112018006237A2 (pt) * 2015-09-29 2018-10-09 Celgene Corp proteínas de ligação a pd-1 e métodos de uso das mesmas
AR108377A1 (es) 2016-05-06 2018-08-15 Medimmune Llc Proteínas de unión biespecíficas y sus usos
WO2018049248A1 (en) * 2016-09-09 2018-03-15 Icellhealth Consulting Llc Oncolytic virus equipped with bispecific engager molecules
US20200188528A1 (en) 2016-12-19 2020-06-18 Fred Hutchinson Cancer Research Center Peptide-antibody compositions and methods of use thereof
CA3061874A1 (en) * 2017-06-22 2018-12-27 Novartis Ag Il-1beta binding antibodies for use in treating cancer

Also Published As

Publication number Publication date
CN114127107A (zh) 2022-03-01
CN114127107B (zh) 2024-11-01
AU2020252191A1 (en) 2021-11-18
EP3947449A1 (en) 2022-02-09
EP3947449A4 (en) 2022-09-07
JP2022525238A (ja) 2022-05-11
KR20220004067A (ko) 2022-01-11
CA3135838A1 (en) 2020-10-08
US11718673B2 (en) 2023-08-08
WO2020205875A1 (en) 2020-10-08
US20200308285A1 (en) 2020-10-01

Similar Documents

Publication Publication Date Title
AU2017310163B2 (en) Heterodimeric Fc-fused cytokine and pharmaceutical composition comprising the same
CN112739379B (zh) 包含OX40抗原结合位点的Fc结合片段
US11718673B2 (en) Bispecific binding molecules that target the tumor microenvironment and an immune checkpoint protein
TWI824215B (zh) 抗ｌｉｌｒｂ１抗體和彼之用途
TW202035451A (zh) 含有受限cd3結合域及受體結合區之多重特異性多肽構築體及其使用方法
TW201927824A (zh) 三鏈抗體、其製備方法及其用途
CN112384533A (zh) 抗-ror抗体构建体
JP2023504016A (ja) Ｃｄ３およびｂｃｍａに対する抗体およびそれらから作製した二重特異性結合タンパク質
TW202535924A (zh) 抗ｄｌｌ３嵌合抗原受體及其用途
BR112021000397A2 (pt) Fragmentos de ligação fc que compreendem um sítio de ligação a antígeno cd137
JP7578869B2 (ja) Ｃｄ３００ｃ抗原またはその受容体に特異的に結合するキメラ抗原受容体
WO2021008523A1 (zh) 抗tigit抗体及其应用
CN112513077A (zh) 高效表达的egfr和pd-l1双特异性结合蛋白
TWI868154B (zh) 用於與細胞激素抑制劑組合使用之抗t細胞抗原結合分子
TW202208438A (zh) 抗ｌｉｌｒｂ１抗體或其抗原結合片段、製備其的方法、藥物組成物、核酸分子、重組載體以及重組細胞
CN114746451A (zh) TGFβ/PD-L1双特异性结合蛋白
CN118555973A (zh) 蛋白质复合物的组合物及其使用方法
WO2023186113A1 (zh) 靶向pd-l1和cd40的抗原结合蛋白及其制备和应用
WO2022072697A2 (en) Bispecific binding molecules 2
CN120344262A (zh) 抗-5t4抗体及用途
WO2024076864A2 (en) Anti-ror1 antibodies and uses thereof
WO2025147472A1 (en) Anti-611-ctf p95her2 antibodies and uses thereof
HK40129592A (zh) 抗-5t4抗体及用途
TW202515907A (zh) 新穎抗切斷型突變calr-cd3雙特異性抗體及醫藥組合物
WO2024182475A2 (en) Anti-ror2 antibodies and uses thereof